2026 ICD-10-CM Diagnosis Code G63Polyneuropathy in diseases classified elsewhere

ICD-10-CM Codes›G00–G99›G60-G65›G63

ICD-10-CM G63
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

G63 is a billable ICD-10-CM diagnosis code for polyneuropathy in diseases classified elsewhere. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 73 through 74. The code is a manifestation code that cannot be reported as the principal diagnosis. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Polyneuropathies.

G63 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 75 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 75, ESRD (V21) category 75, ESRD (V24) category 75, and RxHCC Part D (V08) category 158 for payment year 2026.

Code Identity

ICD-10-CM Code
G63
Billable Status
Yes — Valid for Submission
Code Describes
Polyneuropathy in diseases classified elsewhere
Short Description
Polyneuropathy in diseases classified elsewhere
Same as the full description in the CMS dataset.
Chapter
G60-G65
Polyneuropathies and other disorders of the peripheral nervous system

Code Classification

ChapterG00–G99Diseases of the nervous system
SectionG60-G65Polyneuropathies and other disorders of the peripheral nervous system
CategoryG63Polyneuropathy in diseases classified elsewhere
This CodeG63Polyneuropathy in diseases classified elsewhere

Code EditsBilling

Medicare Code Editor checks that affect claim validity for G63.

Manifestation diagnoses
Manifestation codes describe the manifestation of an underlying disease, not the disease itself, and therefore should not be used as a principal diagnosis.

Medicare Risk Adjustment (HCC)Billing

G63 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.

CMS-HCC V28 (Medicare Advantage Payment Model)
Not mapped
Dropped in V28 see all codes that no longer risk-adjust
Prior Model (CMS-HCC V24)
HCC 75
V24 retired last contributed to a Medicare Advantage risk score in payment year 2025
Other CMS Models
PACE (CMS-HCC V22): HCC 75 · ESRD (V21): HCC 75 · ESRD (V24): HCC 75
ESRD V21 weights: 0.059 dialysis, 0.284–0.323 functioning graft · ESRD V24 weights: 0.074 dialysis, 0.344–0.599 functioning graft
Part D (RxHCC)
RxHCC 158 — Inflammatory and Toxic Neuropathy
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Bacterial infection of peripheral nerve
  • Cytomegaloviral polyneuropathy
  • Gouty neuritis
  • Hepatic neuropathy
  • Leprosy neuropathy
  • Leprosy polyneuropathy
  • Myxedema neuropathy
  • Neurological disorder due to obesity
  • Neurolymphomatosis
  • Neuropathy associated with dysproteinemias
  • Neuropathy associated with endocrine disorder
  • Neuropathy associated with hypoglycemia
  • Neuropathy caused by bacterial toxin
  • Neuropathy due to folic acid deficiency
  • Neuropathy due to nutritional deficiency
  • Neuropathy due to obesity
  • Neuropathy due to vitamin B deficiency
  • Neuropathy in acromegaly
  • Neuropathy in benign monoclonal gammopathy
  • Neuropathy in blood dyscrasias
  • Neuropathy in cryoglobulinemia
  • Neuropathy in macroglobulinemia
  • Neuropathy in renal failure
  • Niacin deficiency
  • Paraneoplastic neuropathy
  • Paraneoplastic peripheral neuropathy
  • Pellagra
  • Pellagra neuropathy
  • Peripheral neuropathy caused by toxin
  • Peripheral neuropathy due to multiple micronutrient deficiencies
  • Peripheral neuropathy due to obesity
  • Peripheral neuropathy due to overweight
  • POEMS syndrome
  • Polyneuropathy associated with another disorder
  • Polyneuropathy caused by drug
  • Polyneuropathy co-occurrent and due to systemic connective tissue disorder
  • Polyneuropathy due to classical cystic fibrosis
  • Polyneuropathy due to disorder of parathyroid gland
  • Polyneuropathy due to vitamin B deficiency
  • Polyneuropathy in collagen malignant disease
  • Polyneuropathy in collagen vascular disease
  • Polyneuropathy in disseminated lupus erythematosus
  • Polyneuropathy in pellagra
  • Polyneuropathy in polyarteritis nodosa
  • Polyneuropathy in rheumatoid arthritis
  • Porphyric polyneuropathy
  • Secondary peripheral neuropathy
  • Sensory polyneuropathy
  • Sensory polyneuropathy due to vitamin E deficiency
  • Toxic polyneuropathy
  • Uremic neuropathy
  • Uremic polyneuropathy

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Code First

Type 1 Excludes

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NVS015
Polyneuropathies
Default principal diagnosis: inpatient No · outpatient No

Clinical InformationClinical

  • Pellagra

    a disease due to deficiency of niacin, a b-complex vitamin, or its precursor tryptophan. it is characterized by scaly dermatitis which is often associated with diarrhea and dementia (the three d's).

  • Herpesvirus 2, Gallid

    the type species of the genus mardivirus in the family herpesviridae. it is the etiologic agent of marek disease, infecting domestic fowl and wild birds.

  • Neurolymphomatosis

    infiltration of the nervous system by malignant lymphoma cells.

  • POEMS Syndrome

    a multisystemic disorder characterized by a sensorimotor polyneuropathy (polyneuropathies), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. other clinical features which may be present include edema; cachexia; microangiopathic glomerulopathy; pulmonary hypertension (hypertension, pulmonary); cutaneous necrosis; thrombocytosis; and polycythemia. this disorder is frequently associated with osteosclerotic myeloma. (from adams et al., principles of neurology, 6th ed, p1335; rev med interne 1997;18(7):553-62)

  • Chronic Toxic Polyneuropathy

    neuropathy affecting multiple nerves that is caused by prolonged exposure to toxic substances.

  • Uremic Neuropathy

    neuropathy resulting from uremia.

  • Toxic Polyneuropathy

    polyneuropathy that is caused by exposure to toxins.

Patient EducationClinical

Peripheral Nerve Disorders

Nerves are like wires that carry messages back and forth between your brain and your body. Your peripheral nerves branch off from your brain and spinal cord and connect to all parts of your body, including your muscles and organs.

The full article covers:

  • What are peripheral nerves?
  • What are peripheral nerve disorders?
  • What causes peripheral nerve disorders?
  • What are the symptoms of peripheral nerve disorders?
  • How are peripheral nerve disorders diagnosed?
  • What are the treatments for peripheral nerve disorders?
  • Can peripheral nerve disorders be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert G63 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
357.4 Neuropathy in other dis
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About G63Overview

What is the ICD-10 code for polyneuropathy in diseases classified elsewhere?

The ICD-10-CM code for polyneuropathy in diseases classified elsewhere is G63. It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is G63 (Polyneuropathy in diseases classified elsewhere) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report polyneuropathy in diseases classified elsewhere on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does G63 group to?

On inpatient claims, polyneuropathy in diseases classified elsewhere maps to MS-DRG 73, 74, with relative weights from 1.0308 to 1.6043 depending on complications. Higher weights mean higher Medicare reimbursement.

Can G63 be a principal diagnosis?

No. This is a manifestation code: polyneuropathy in diseases classified elsewhere describes the manifestation of an underlying disease rather than the disease itself, so the underlying condition is sequenced first.

What is the ICD-9 equivalent of G63?

Under the General Equivalence Mappings, polyneuropathy in diseases classified elsewhere converts to ICD-9-CM 357.4 (neuropathy in other dis). The mapping is approximate, so confirm the match fits the documentation.

Does G63 risk-adjust for Medicare Advantage payment?

Not for Medicare Advantage. G63 mapped to HCC 75 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 75 (Myasthenia Gravis/Myoneural Disorders and Guillain-Barre Syndrome/Inflammatory and Toxic Neuropathy), ESRD (V21) category 75 (Polyneuropathy), ESRD (V24) category 75 (Myasthenia Gravis/Myoneural Disorders and Guillain-Barre Syndrome/Inflammatory and Toxic Neuropathy), and RxHCC Part D (V08) category 158 (Inflammatory and Toxic Neuropathy).